FR2774589A3 - Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin - Google Patents

Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin Download PDF

Info

Publication number
FR2774589A3
FR2774589A3 FR9801794A FR9801794A FR2774589A3 FR 2774589 A3 FR2774589 A3 FR 2774589A3 FR 9801794 A FR9801794 A FR 9801794A FR 9801794 A FR9801794 A FR 9801794A FR 2774589 A3 FR2774589 A3 FR 2774589A3
Authority
FR
France
Prior art keywords
mucopolysaccharidase
escin
compositions
compositions according
slimming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9801794A
Other languages
French (fr)
Other versions
FR2774589B3 (en
Inventor
Jean Noel Thorel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9801794A priority Critical patent/FR2774589B3/en
Publication of FR2774589A3 publication Critical patent/FR2774589A3/en
Application granted granted Critical
Publication of FR2774589B3 publication Critical patent/FR2774589B3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cosmetic slimming compositions contain a mucopolysaccharidase (I) and escin (II).

Description

La présente invention à pour objet de nouvelles compositions cosmétiques amincissantes. Dans ce qui suit, on désignera par le même adjectif "amincissantes" des compositions entraînant non seulement un amincissement, mais également une mobilisation des graisses entraînant un réel amaigrissement. The present invention relates to new slimming cosmetic compositions. In what follows, the same adjective will designate "slimming" compositions which cause not only a thinning, but also a mobilization of fats resulting in real weight loss.

La cellulite est la manifestation d'un certain déséquilibre métabolique au niveau des cellules adipeuses. II apparaît une prolifération des sites ss-adrénergiques sur la membrane des adipocytes, qui favorise la lipogenèse au détriment de la lipolyse. De plus, I'augmentation de la couche adipeuse s'accompagne d'un développement et d'une réticulation du tissu scléro-hyalin qui encapsule les adipocytes. Cellulite is the manifestation of a certain metabolic imbalance in the fat cells. There is a proliferation of ss-adrenergic sites on the adipocyte membrane, which promotes lipogenesis at the expense of lipolysis. In addition, the increase in the adipose layer is accompanied by the development and crosslinking of the sclero-hyaline tissue which encapsulates the adipocytes.

Les produits cosmétiques amincissants contiennent généralement des principes actifs stimulants la lipolyse. Or, les modifications structurales du tissu scléro-hyalin empêchent le contact entre les principes actifs et les sites récepteurs des adipocytes. Si ces actifs ont une bonne activité in vitro sur les adipocytes en culture, ils ont bien souvent des activités faibles ou inexistantes lorsqu'ils sont utilisés par les consommateurs. Slimming cosmetic products generally contain active ingredients that stimulate lipolysis. However, the structural modifications of the sclero-hyaline tissue prevent the contact between the active principles and the receptor sites of the adipocytes. If these active agents have a good activity in vitro on adipocytes in culture, they very often have weak or nonexistent activities when they are used by consumers.

II subsiste donc le besoin de compositions cosmétiques amincissantes capables à la fois d'attaquer le tissu scléro-hyalin et de stimuler la lipolyse. There therefore remains the need for slimming cosmetic compositions capable of both attacking the sclero-hyaline tissue and of stimulating lipolysis.

A la suite d'importantes recherches menées dans le domaine évoqué ci-dessus, la demanderesse a envisagé l'utilisation d'une mucopolysaccharidase en association avec de l'escine. Following significant research carried out in the field mentioned above, the Applicant has considered the use of a mucopolysaccharidase in association with escin.

Ainsi, conformément à l'objet de la présente invention, il est maintenant proposé de nouvelles compositions cosmétiques amincissantes qui sont essentiellement caractérisées par le fait qu'elles contiennent une mucopolysaccharidase et de l'escine.  Thus, in accordance with the object of the present invention, new slimming cosmetic compositions are now proposed which are essentially characterized by the fact that they contain a mucopolysaccharidase and escin.

La mucopolysaccharidase permet par son activité enzymatique, d'éliminer la gangue qui entoure les adipocytes. L'escine masque les sites récepteurs p-adrénergiques, présents sur la membrane des adipocytes, et active ainsi la lipolyse. The mucopolysaccharidase allows by its enzymatic activity, to eliminate the gangue which surrounds the adipocytes. The escin masks the p-adrenergic receptor sites, present on the adipocyte membrane, and thus activates lipolysis.

Suivant un mode particulièrement préféré de la présente invention, la mucopolysaccharidase est une hyaluronidase, utilisée dans des proportions comprises entre 0,001 et 10 % en poids par rapport au poids total de la composition, lorsque l'activité enzymatique est de 300 000 Ul/g, et de préférence comprises entre 0,01 et 2 %. According to a particularly preferred embodiment of the present invention, the mucopolysaccharidase is a hyaluronidase, used in proportions of between 0.001 and 10% by weight relative to the total weight of the composition, when the enzymatic activity is 300,000 IU / g, and preferably between 0.01 and 2%.

Selon un mode de réalisation avantageux de l'invention,
'escine est apportée sous forme d'extrait de marron d'lnde. La proportion en escine des compositions de l'invention sont de préférence comprises entre 0,001 et 50 % en poids par rapport au poids total de la composition, et mieux encore, entre 0,1 et 5 %.
According to an advantageous embodiment of the invention,
escine is brought in the form of extract of horse chestnut The steep proportion of the compositions of the invention are preferably between 0.001 and 50% by weight relative to the total weight of the composition, and better still, between 0.1 and 5%.

Les compositions selon l'invention peuvent en outre contenir tous les constituants classiquement utilisés, notamment autres actifs amincissants, dans les compositions cosmétiques amincissantes tels que par exemple les dérivés xanthiques (caféine, théophylline), les dérivés du silicium organique (monométhylsilanétriol, diméthyl silanol}. Leur proportion préférentielle est comprise entre 1 et 20 % en poids par rapport au poids total de la composition, et mieux encore entre 1 et 10 %. The compositions according to the invention may also contain all the constituents conventionally used, in particular other slimming active agents, in cosmetic slimming compositions such as for example the xanthic derivatives (caffeine, theophylline), the organic silicon derivatives (monomethylsilanetriol, dimethyl silanol). Their preferred proportion is between 1 and 20% by weight relative to the total weight of the composition, and better still between 1 and 10%.

La composition selon l'invention peut se présenter sous toutes les formes galéniques classiquement utilisées dans les compositions cosmétiques. The composition according to the invention can be in all the galenical forms conventionally used in cosmetic compositions.

Des exemples concrets, mais nullement limitatifs, illustrant l'invention vont maintenant être donnés. Concrete, but in no way limiting, examples illustrating the invention will now be given.

Exemple 1:
Mucopolysaccharidase 0, 1%
Escine 2%
Stéareth-20 0,2 %
Méthyl paraben 0,25%
Chlorure de calcium 0,01%
Chlorure de magnésium 0,01 %
Eau qsp 100 %
Stéareth- 2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1 %
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 %
Exemple 2:
Mucopolysaccharidase 0,05 %
Escine 0,1 %
Silicium 2%
Stéareth-20 0,2 %
Méthyl paraben 0,25 %
Chlorure de calcium 0,01 %
Chlorure de magnésium 0,01 %
Eau qsp. 100 %
Stéareth-2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1%
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 %
Exemple 3
Mucopolysaccharidase 0,05 %
Escine 0,1 %
Théophylline 0,5 %
Caféine 0,5 %
Stéareth-20 0,2 %
Méthyl paraben 0,25 %
Chlorure de calcium 0,01 %
Chlorure de magnésium 0,01 %
Eau qsp. 100 %
Stéareth-2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1%
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 %
Example 1:
Mucopolysaccharidase 0, 1%
Escine 2%
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs 100%
Steareth- 2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%
Example 2:
Mucopolysaccharidase 0.05%
Escin 0.1%
2% silicon
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs. 100%
Steareth-2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%
Example 3
Mucopolysaccharidase 0.05%
Escin 0.1%
Theophylline 0.5%
Caffeine 0.5%
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs. 100%
Steareth-2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%

Claims (8)

1 - Compositions cosmétiques amincissantes caractérisées par le fait qu'elles contiennent une mucopolysaccharidase et de l'escine. 1 - Slimming cosmetic compositions characterized by the fact that they contain a mucopolysaccharidase and escin. REVENDICATIONS 2 - Compositions selon la revendication i, caractérisées par le fait que ladite mucopolysaccharidase est une hyaluronidase. 2 - Compositions according to claim i, characterized in that said mucopolysaccharidase is a hyaluronidase. 3 - Compositions selon la revendication 2, caractérisées par le fait que la teneur en hyaluronidase est comprise entre 0,001 et 10 % en poids par rapport au poids total de la composition. 3 - Compositions according to claim 2, characterized in that the hyaluronidase content is between 0.001 and 10% by weight relative to the total weight of the composition. 4 - Compositions selon la revendication 3 caractérisées par le fait que ladite teneur est comprise entre 0,01 et 2 %. 4 - Compositions according to claim 3 characterized in that said content is between 0.01 and 2%. 5 - Compositions selon l'une quelconque des revendications précédentes caractérisées par le fait que la teneur en escine est comprise entre 0,001 et 50% en poids par rapport au poids total de la composition. 5 - Compositions according to any one of the preceding claims, characterized in that the escine content is between 0.001 and 50% by weight relative to the total weight of the composition. 6 - Compositions selon la revendication 5, caractérisées par le fait que ladite teneur est comprise entre 0,1 et 5%. 6 - Compositions according to claim 5, characterized in that said content is between 0.1 and 5%. 7 - Compositions selon l'une quelconque des revendications précédentes, caractérisées par le fait que l'escine est apportée sous forme d'extrait de marron d'lnde. 7 - Compositions according to any one of the preceding claims, characterized in that the escin is provided in the form of extract of chestnut from India. 8 - Compositions selon l'une quelconque des revendications précédentes, caractérisées par le fait qu'elles renferment de 1 à 20 % en poids par rapport au poids total de la composition, d'actifs amincissants classiquement utilisés dans les compositions cosmétiques amincissantes, et préférentiellement de 1 à 10 %.  8 - Compositions according to any one of the preceding claims, characterized in that they contain from 1 to 20% by weight relative to the total weight of the composition, slimming active agents conventionally used in cosmetic slimming compositions, and preferably from 1 to 10%.
FR9801794A 1998-02-10 1998-02-10 SLIMMING COSMETIC COMPOSITIONS Expired - Lifetime FR2774589B3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9801794A FR2774589B3 (en) 1998-02-10 1998-02-10 SLIMMING COSMETIC COMPOSITIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801794A FR2774589B3 (en) 1998-02-10 1998-02-10 SLIMMING COSMETIC COMPOSITIONS

Publications (2)

Publication Number Publication Date
FR2774589A3 true FR2774589A3 (en) 1999-08-13
FR2774589B3 FR2774589B3 (en) 2000-01-07

Family

ID=9522977

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9801794A Expired - Lifetime FR2774589B3 (en) 1998-02-10 1998-02-10 SLIMMING COSMETIC COMPOSITIONS

Country Status (1)

Country Link
FR (1) FR2774589B3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541127A1 (en) * 2003-12-10 2005-06-15 L'oreal Use of modulators of aquaglyceroporins as slimming agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720510A1 (en) * 1976-05-07 1977-11-24 Biotherm COSMETIC AGENT WITH SLIMMING AND ANTICELLULITIS EFFECT
DE2729010A1 (en) * 1976-07-02 1978-01-12 Ana Lab Sa MEDICINAL PRODUCTS FOR THE TREATMENT OF CELLULITE AND EXCESSIVE FAT
FR2400902A1 (en) * 1977-08-22 1979-03-23 Ana Laboratoires Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720510A1 (en) * 1976-05-07 1977-11-24 Biotherm COSMETIC AGENT WITH SLIMMING AND ANTICELLULITIS EFFECT
DE2729010A1 (en) * 1976-07-02 1978-01-12 Ana Lab Sa MEDICINAL PRODUCTS FOR THE TREATMENT OF CELLULITE AND EXCESSIVE FAT
FR2400902A1 (en) * 1977-08-22 1979-03-23 Ana Laboratoires Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R. MAFFEI FACINO: "Anti-Elastase and Anti-Hyaluronidase Activities of Saponins and Sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: Factors Contributing to their Efficacy in the Treatment of Venous Insufficiency", ARCH. PHARM., vol. 328, no. 10, 1995, Weinheim Germany), pages 720 - 724, XP002082552 *
R. MAFFEI FACINO: "Efficacy of Topically Applied Hedera Helix L. Saponins for Treatment of Liposclerosis (so-called "Cellulitis")", ACTA THERAPEUTICA, vol. 16, no. 4, 1990, pages 337 - 349, XP002082551 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1541127A1 (en) * 2003-12-10 2005-06-15 L'oreal Use of modulators of aquaglyceroporins as slimming agents
FR2863492A1 (en) * 2003-12-10 2005-06-17 Oreal USE OF AQUAGLYCEROPORIN MODULATORS AS SLIMMING

Also Published As

Publication number Publication date
FR2774589B3 (en) 2000-01-07

Similar Documents

Publication Publication Date Title
US4863725A (en) Novel clear oil-free moisturizer composition
JP4601898B2 (en) Topical lightening composition and method of use
US8394363B2 (en) Cosmetic rinsable mask type composition for skin care
FR2669537A1 (en) SLIMMING COMPOSITION BASED ON ALPHA-2-BLOCKERS.
FR2499405A1 (en) SLIMMING AND ANTI-CELLULAR COSMETIC COMPOSITION BASED ON A PLANT EXTRACT CONTAINING SAPONINS, AN EXTRACT FROM ARNICA MONTANA L. AND A COLA NUT EXTRACT AND METHOD OF APPLICATION THEREOF
JP4182183B2 (en) Slimming skin cosmetics
KR20110014221A (en) Method and compositions for improving skin and body appearance
JP2001506240A (en) Cosmetic cleansing skin care preparation containing plant extract and seaweed extract
FR2788058A1 (en) SLIMMING COSMETIC COMPOSITIONS
CN110215407A (en) A kind of anti-ageing compact composition and its cosmetics and application
EP0655235B1 (en) Slimming composition
EP0450669B1 (en) Cosmetic or dermatological slimming or anticellulitis composition containing cola extracts into liposomes
JP2000229834A (en) Cosmetic
US20100189754A1 (en) Oil Based Composition For External Use On Skin For Enhancing Percutaneous Absorption
CA1091581A (en) Cosmetic composition against cellulitis and for slenderizing
FR2725898A1 (en) TOPICAL APPLICATION PRODUCT CONTAINING A LIPASE AND A HYDROXYACID PRECURSOR
FR2774589A3 (en) Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin
FR2748659A1 (en) TOPICAL SLIMMING COMPOSITION
JP3537671B2 (en) Lipolysis accelerator and skin cosmetic for slimming
FR2758724A1 (en) Controlling cellulite and fat deposition
JPH0528203B2 (en)
EP0971722B1 (en) An aphrodisiac for application to the sexual organs
EP1551365A1 (en) Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor
JP2001163762A (en) Sliming agent
JP4842170B2 (en) Solid powder cosmetics

Legal Events

Date Code Title Description
CL Concession to grant licences
CL Concession to grant licences
AU Other action affecting the ownership or exploitation of an industrial property right